Esketamine's Therapeutic Effect on Anhedonia: A Post-hoc of a Randomized Controlled Trial
Research Square July 20, 2026
Esketamine's Therapeutic Effect on Anhedonia: A Post-hoc of a Randomized Controlled Trial
19 results for "Meta-analysis: What did research on Esketamine find in July 2026?"
Topics
(Es)ketamine in functional neurological disorder: a systematic review
Frontiers in Psychiatry July 20, 2026 Bruce Tamilson, Michael Chitolie, Jan Coebergh et al.
Background and aimFunctional neurological disorder (FND) is a common and disabling condition for which effective treatments remain limited. Clinical outcomes are often variable, particularly in chronic and comorbid presentations. Ketamine and esketamine are increasingly used across a range of neuropsychiatric conditions. This review aimed to synthesise the existing evidence regarding their use...
Clinical guidance on the use of esketamine nasal spray for patients with treatment resistant depression: A European Delphi consensus report.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology July 17, 2026 Allan H. Young, Bernhard T Baune, Beatrice Benatti et al.
Esketamine nasal spray (NS) is an established treatment for patients with treatment resistant depression (TRD). To further optimise real-world outcomes, consensus is needed regarding strategies to enhance patient outcomes and decision-making factors for pivotal timepoints in esketamine NS treatment. This modified Delphi panel (3 rounds) established expert consensus (≥80% agreement) from 30...
Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression
Zenodo (CERN European Organization for Nuclear Research) July 17, 2026 Bartosz Niciński, Magdalena Kloc, Ewa Wiench, Natasza Millan, Aleksandra Blicharz, Wojciech Kozdraś, Lidia Kozaczko, Gabriela Szewczyk, Elżbieta Bukowczan, Alicja Zając, Damian Broda, Alicja Benecka
Major depressive disorder is a highly burdensome psychiatric condition worldwide, and many patients do not achieve full remission after standard monoaminergic antidepressant treatment. This has contributed to growing interest in rapid-acting antidepressant interventionstargeting neurobiological pathways beyond traditional serotonin, norepinephrine, and dopamine mechanisms. This review...
Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial.
Journal of Affective Disorders July 16, 2026 Sara Massetti, Sanne Y Smith-Apeldoorn, Jolien K E Veraart et al.
Ketamine and its enantiomer esketamine are efficacious in 30-35% of the patients with treatment-resistant depression (TRD). Increased serum brain-derived neurotrophic factor (BDNF) following treatment has been proposed as a potential biomarker of antidepressant response. This is based on studies evaluating single intravenous ketamine treatment. BDNF expression at different treatment schedules...
Is the reduction in suicidal ideation and deliberate self-harm during intranasal esketamine treatment independent of antidepressant response? A secondary, longitudinal analysis of a real-world TRD cohort with and without comorbid borderline personality disorder
Open MIND July 13, 2026 Vassilis Martiadis, Fabiola Raffone
In acute trials of intravenous and intranasal ketamine/esketamine, the rapid anti-suicidal effect appears to be at least partly independent of the overall antidepressant response. That question has, to our knowledge, never been examined in a real-world esketamine cohort followed for six months, nor in a sample enriched for comorbid borderline personality disorder (BPD), a population excluded...
S-ketamine, but not R-ketamine, transiently suppresses front-loaded binge-like alcohol self-administration in male rats
July 12, 2026 Fahd François Hilal, Méléna Dreinaza, Quentin Lebel et al.
Background and Purpose: Ketamine has emerged as a promising treatment candidate for alcohol use disorder (AUD), yet whether its S- and R-enantiomers differentially regulate ongoing binge-like alcohol self-administration remains unknown. We compared the acute and repeated effects of S- and R-ketamine in a chronic binge-like, front-loaded operant alcohol self-administration paradigm. Experimental...
Esketamine for treatment-resistant depression: Comparing two maintenance schedules in an observational real-world study
Research Square July 9, 2026 Samuel Westenhöfer, Yamina Ehrt, Barbora Provaznikova et al.
Abstract Background : Treatment-resistant depression (TRD) is associated with substantial clinical and socioeconomic burden. Intranasal esketamine has shown efficacy for TRD in clinical trials and real-world studies. However, evidence on optimal maintenance scheduling is limited. We therefore investigated whether two maintenance schedules differing in their inter-dose intervals were associated...
Real-world outcomes of intranasal esketamine and intravenous ketamine induction therapy for treatment-resistant depression in a community clinic: a retrospective cohort study
Frontiers in Psychiatry July 9, 2026 Patrice A. Bellanti, Jordan Lewis, Brian Seifferth et al.
Introduction Intravenous (IV) ketamine and intranasal esketamine are NMDA receptor antagonists used for treatment-resistant depression (TRD). Both have demonstrated efficacy in controlled trials, but observational evidence from real-world community settings is limited. Methods We conducted a single-center retrospective cohort study of adults aged 18 to 65 receiving induction therapy for TRD...
Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis
Frontiers in Psychiatry July 3, 2026 Jingqiang Xie, Chunying Pu, Mingyue Sun
Treatment-resistant depression (TRD) remains a major clinical challenge. Intranasal esketamine, used adjunctively with an oral antidepressant, has been evaluated in randomized trials, but uncertainty persists regarding the magnitude and consistency of benefit, durability, and key harms. This systematic review and meta-analysis included randomized controlled trials comparing intranasal...
Real‐World Effectiveness and Cost‐Differential of Intranasal Esketamine Versus Intramuscular Ketamine
Psychiatric Research and Clinical Practice July 2, 2026 Kush V. Bhatt, Tara Austin, Danny Alam et al.
Objective This study evaluated whether intramuscular (IM) ketamine is non‐inferior to intranasal (IN) esketamine for treatment‐resistant depression (TRD) and assessed differences in safety and healthcare costs. Methods In a retrospective, observational sequential cohort at the VA San Diego, 179 Veterans with TRD received eight treatments of either IN esketamine ( n = 89) or IM ketamine ( n =...
QUALITY OF LIFE AND PRODUCTIVITY AMONG ESKETAMINE RESPONDERS IN A REAL-WORLD STUDY IN AUSTRALIA AND NEW ZEALAND
Journal of Psychiatric Research July 1, 2026 Malcolm Hopwood, David Codyre, David Barton et al.
Treatment-resistant depression (TRD) is associated with severe depression, low quality of life (QoL) and reduced work productivity, which may increase risk of relapse, suicide and suboptimal response to treatment. Esketamine nasal spray plus a newly-initiated oral antidepressant (esketamine+OAD) has been shown to improve depression symptoms, QoL and productivity in patients with TRD; however...
Dissociation and Antidepressant Response to Subcutaneous Esketamine: A Clinical Study
Journal of Psychiatric Research July 1, 2026 K S de Freitas Goncalves, Vagner Deuel O de Tavares, Fernanda Palhano-Fontes et al.
ABSTRACT: Introduction Ketamine and esketamine have reemerged as promising interventions for treatment-resistant depression (TRD), yet debate persists regarding the clinical relevance of acute dissociative experiences. This secondary exploratory analysis examined the relationship between dissociative experiences induced by subcutaneous esketamine and antidepressant response in patients with...
Targeting TLR4/PPARα-mediated neuroinflammation in the prefrontal cortex: S-ketamine and S-HNK rapidly alleviate depression-like behaviors
Journal of Neuroimmunology July 1, 2026 Quanfeng Zhu, Xiaoyue Zhou, Huangling Gao et al.
Neuroinflammation, particularly Toll-like receptor 4 (TLR4)-mediated signaling, plays a critical role in the pathophysiology of depression. This study aimed to investigate the mechanisms by which S-ketamine (S-ket) and S-hydroxynorketamine (S-HNK) modulate TLR4 and peroxisome proliferator-activated receptor alpha (PPARα) signaling in the prefrontal cortex (PFC) to exert antidepressant effects....
Case Report: Intranasal esketamine and accelerated intermittent theta-burst stimulation for severe treatment-resistant depression with suicidal ideation
Frontiers in Psychiatry July 1, 2026 Chun-Hung Chang, Yu-Der Hsia, W Liu et al.
Introduction Treatment-resistant major depressive disorder with high-risk suicidal ideation is a psychiatric emergency that requires rapid and effective intervention. Although intranasal esketamine and intermittent theta-burst stimulation (iTBS) are time-efficient therapeutic options, clinical reports describing their combined use in an accelerated inpatient schedule are limited, particularly...
Effect of intraoperative esketamine on moderate-to-severe depressive symptoms in major surgery patients: A randomized clinical trial.
Pharmacological Research July 1, 2026 Yang Zhou, Wanchen Sun, Yuxuan Fu et al.
Perioperative depressive symptoms (PDSs) are common among patients who undergo major surgery and can lead to worse clinical outcomes. Esketamine has been reported to alleviate PDSs in patients undergoing certain types of surgery. However, there is a lack of evidence from large-scale, multisurgery studies to support its therapeutic effects in individuals with preexisting moderate-to-severe PDSs....
N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine.
Neuropharmacology July 1, 2026 Anne Nathalia De Sousa-Silva, Clarissa de Almeida Moura, Carina Ioná De Oliveira Torres et al. 1 citation
N,N-dimethyltryptamine (DMT) is an naturally occurring indoleamine with hallucinogenic and antidepressant effects in humans. Here, we compared the effects of DMT and S-ketamine, a fast-acting antidepressant, in helpless mice. To induce helplessness, male single and group-housed mice were exposed to inescapable footshock stress; only helpless animals were subsequently treated with S-ketamine 10...
Clinical Predictors of Antidepressant Effects of Ketamine and Esketamine in Treatment-Resistant Unipolar and Bipolar Depression: A Systematic Review
CNS Drugs July 1, 2026 Omer A. Syed, Valentyn Sobolenko, Sean M. Nestor et al.
Background and Objective Ketamine and esketamine have emerged as effective and rapid-acting interventions for treatment-resistant depression. Nevertheless, the best-suited candidates for these treatments are not clear. As such, the ability to personalize treatment selection and parameters would likely improve therapeutic response. This systematic review synthesized the literature on clinical...
Psychedelics as a potential treatment for borderline personality disorder: A narrative review.
Psychiatry Research July 1, 2026 Erin Artna, Guneet Sandhu, Noah Chisamore et al. 1 citation
Borderline personality disorder (BPD) is a serious mental illness with high rates of morbidity and stigma; however, successful remission is frequently limited by a paucity of accessible treatment options. In an era of growing interest in psychedelics as novel psychiatric treatment modalities, patients with BPD are often excluded from research due to perceived safety risks, particularly...